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Abstract—The amount of 131I necessary for successful ablation 
in patients with differentiated thyroid cancer (DTC) is still sub­
ject to debate. This study investigates the relationship of the 
absorbed dose of radiation to the blood while administering 
131I activity with several other parameters in DTC patients. 
This prospective study included 90 DTC patients who were 
classified into three groups according to their level of dosage: 
3.7 GBq (38.9%), 5.55 GBq (55.6%), and 7.4 GBq (5.5%). 
Blood dosimetry of treated patients was performed using ex­
ternal whole-body counting with a Geiger Muller dosimeter 
located 2 m away from the patients. Dose rate was measured 
at 2, 4, 5, 24, and 48 h after the administration of radioiodine. 
Based on the results of whole-body dose rate measurements, 
48 h after administration of 3.7, 5.55, and 7.4 GBq of radio-
iodine, absorbed doses to patients’ blood were estimated at 0.49 ± 
0.12, 0.71 ± 0.21, and 0.76 ± 0.11 Gy, respectively. Increasing radio-
iodine dosage from 3.7 GBq to 5.55 GBq significantly increased 
blood dose, while there was no significant difference in blood dose 
between radioiodine dosages of 5.55 GBq and 7.4 GBq. The ab­
sorbed dose to the blood was significantly correlated to the pa­
tients’ gender and the presence of lymph node metastases, but 
it was not significantly correlated to the type of pathology and 
regional or distant metastases. Ablation activities exceeding 
5.55 GBq produce no further increase in the accumulated activ­
ity per volume of blood. The literature regarding this issue is 
scarce, and further studies are required to verify these prelimi­
nary results. 
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INTRODUCTION 
EACH YEAR, 26,000 patients in the United States and 1,500 
in the United Kingdom are diagnosed with thyroid-related 
cancers (Hackshaw et al. 2007). The reports reveal that the 
rate of differentiated thyroid cancers (DTC) have increased 
40% in the United States from 2000 to 2005 (Azizmohammadi 
et al. 2013; Hackshaw et al. 2007). DTC is the most common 
sub-category of thyroid cancer. Thirty percent of patients 
suffer from recurrence of the disease. 
Routine treatment strategy for DTC consists of a total 
thyroidectomy followed by radiation therapy with radioio­
dine to ablate remaining thyroid tissue (Verburg et al. 
2011). According to recent research, DTC therapy combin­
ing surgery with radioiodine ablation is usually associated 
with a 10‐y survival for 90% of patients (Hackshaw et al. 
2007). Radioiodine ablation for DTC patients matters for 
the following reasons. First, the presence of remnant thy­
roid tissue after surgery makes it difficult to detect and treat 
regional or distant metastases (Miccoli et al. 1998; Van 
Nostrand et al. 2002). Second, thyroid cancers typically 
tend to be multifocal, so residual thyroid tissue will more 
likely include malignant cells. Third, poorly differentiated 
thyroid cancers can become anaplastic carcinoma. In all 
cases, radioiodine ablates malignant and metastatic cells 
that escaped the surgery, reducing the risk of recurrence 
(Henkin et al. 2006). Because this therapy is well known 
as an effective method to treat DTC, it has become an in­
ternationally standard approach (Dietlein et al. 2007; Gharib 
et al. 2010; Hanscheid et al. 2006; Luster et al. 2008). 
After a patient is treated with radioiodine, an important 
following step is the attempt to determine the dose that is 
absorbed in lesion. Up to now, several techniques have been 
established in this regard. One of the first approaches used 
for dosimetry of patients after radioiodine thyroid therapy 
was a method introduced by Benua et al. (1962) that has 
provided a way to calculate the limited dose to blood that 
can be tolerated and also the dose to the lesion per unit of 
administered activity. The procedure describes that the max­
imum amount of administered activity to a patient can be 
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defined as the amount of activity that leads to an absorbed 
dose to blood of 2 Gy. Later, this method was developed 
by Furhang et al. (2002), in which some parameters were 
fitted to patients’ clearance data to provide a dosimetry al­
gorithm. In recent years, Hanscheid et al. (2006) set up do­
simetric procedures in which the need for blood sampling 
to determine patient absorbed dose has been eliminated. 
One important, if controversial, aspect of radioiodine abla­
tion is determining the standard amount of radioiodine ac­
tivity required for an optimally successful ablation. Past trials 
have associated values ranging from 0.99 GBq to 3.7 GBq 
with favorable outcomes in the ablation of remaining tis­
sue in newly diagnosed DTC cases (Sawka et al. 2008). 
Higher dosages are recommended for metastatic cases, but 
these can cause serious complications affecting bone marrow 
and healthy tissues, so activity values are limited to around 
7.4 GBq (Lassmann et al. 2010; Zakani et al. 2011). On the 
other hand, while higher doses of radioiodine increase suc­
cess rates, some studies discovered no further improvement 
in ablation success for amounts higher than 1.85 GBq (Bal 
et al. 2004; Hackshaw et al. 2007). While the optimal amount 
of radioiodine remains subject to debate, a study by Frederik 
AQ3 et al. showed that the absorbed dose to the blood is a more 
useful predictor of ablation success in thyroid cancer pa­
tients than the amount of administered radioiodine (Verburg 
et al. 2011). 
Therefore, the current study investigates whether in­
creasing the administered radioiodine, which may increase 
complications, would necessarily increase its absorbed dose 
to the blood. It also correlates absorbed dose to the blood 
with patients’ gender, age, type of pathology (PTC or pap­
illary thyroid carcinoma and FTC or follicular thyroid car­
cinoma), and whether metastases are in the lymph node, 
regional, or distant. 
METHODS AND MATERIALS 
Ninety (90) DTC patients were included in this study. 
The necessary histological information was obtained from 
patients’ documents. No patients were excluded for any 
reasons due to their gender, age, or pathology. 
All patients underwent external whole-body counting 
to measure the absorbed dose to the blood of the DTC pa­
tients after radioiodine ablation. This method of blood do­
simetry, which does not require blood sampling, is based 
on the fact that 14% of the whole-body residence time is 
attributed to the blood (Hanscheid et al. 2006). Following 
treatment, patients were stratified into three groups who 
were administered 3.7 GBq (38.9%), 5.55 GBq (55.6%), 
and 7.4 GBq (5.5%); then external whole-body counting 
of each patient was performed by a Geiger Muller dosim­
eter. During whole-body counting, the dosimeter was lo­
cated 1 m above ground level at a distance of 2 m behind 
each patient. The first measurement was performed ap­
proximately 2 h after radioiodine administration, with fur­
ther measurements following at 4, 5, 24, and 48 h. An 
exponential decay curve was fitted to the dose measure­
ments to obtain a 48‐h whole-body radioiodine dose-rate 
curve for each patient. 
The following formula, recently published by Hanscheid 
et al. (2009), calculated absorbed dose to the blood per unit 
of administered radioactivity (Dblood/A0) using dose-rate 
curve data: 
!
 
Dblood 15:12 t h0:0188 ð Þ 
ðmGy=MBqÞ¼ − þ � : 
A0 ½wt kgÞ�BLVðmLÞ 
2=3 ½ ð Þ 1n R t �ð 
BLV is the individual blood volume estimated from the 
patient’s weight (wt) and height (ht) according to the 
equation proposed by Retzlaff et al. (1969): 
BLV ¼ 31:9 � ht þ 26:3 � wt - 2402 f or male 
BLV ¼ 56:9 � ht þ 14:1 � wt - 6460 f or female; 
R(t) is radioiodine retention at time t, and t(h) is the time 
after radioiodine injection. The ANOVA test and indepen­
dent t-test compared the various parameters. The correlation 
of absorbed dose to the blood with administered activity of 
radioiodine, gender, age, type of pathology, and lymph node, 
regional, or distant metastases was considered statistically 
significant at p < 0.05. 
RESULTS 
All 90 adult patients enrolled in this study had been 
newly diagnosed with DTC and recently underwent total 
or near-total thyroidectomies: 26 were men (28.9%) and 
64 were women (71.1%); five (5.6%) patients had folli­
cular cancer, 85 (94.4%) patients had papillary cancer, 
46 (51.1%) patients had metastases in the lymph node, 
40 (44.4%) patients had regional metastases, and nine 
(10%) patients had distant metastases. Mean (±SD) of the 
patients’ age, height, and weight were 42.88 (±16.43) y, 
158.49 (±8.66) cm, and 69.62 (±10.61) kg, respectively. 
Based on their height and weight, patients’ individual 
blood volume was estimated at 5,197.90 ± 176.34 mL for 
men and 3,165.95 ± 121.79 mL for women. 
Results of dose rate measurements by Geiger Muller 
dosimeter at various times were used to draw a 48‐h dose-
rate curve. Fig. 1 presents such curves following adminis­
tration of 3.7, 5.55, and 7.4 GBq of radioiodine. 
Based on Hanscheid’s equation and using data of 
BLV and retention measurement, which was calculated 
by normalization of the last measurement (48 h after 
F1 
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T1 
Fig. 1. 48‐h dose-rate curves following administration of 3.7 GBq 
(diamond), 5.55 GBq (rectangle), and 7.4 GBq (triangle) of radioiodine. 
administration of radioiodine) to the initial measurement 
(2 h after administration of radioiodine) of dose rates, ab­
sorbed dose to the blood of patients was determined as 
0.49 ± 0.12, 0.71 ± 0.21, and 0.76 ± 0.11 Gy for administra­
tion of 3.7, 5.55, and 7.4 GBq of radioiodine, respectively. 
Statistical analysis of data revealed that increasing the 
radioiodine dose from 3.7 GBq to 5.55 GBq significantly 
increases the absorbed dose to the blood of patients, while 
no significant difference was observed between patients 
who received doses of 5.55 GBq and 7.4 GBq. 
Table 1 presents the mean (±SD) values of absorbed 
dose to the blood 48 h after radioiodine administration, 
broken down by gender, type of pathology, presence of 
residual thyroid tissue after thyroidectomy, and whether 
there were lymph node, regional, or distant metastases. 
The mean absorbed dose to the blood in male and fe­
male subgroups was estimated to be 0.53 ± 0.14 Gy and 
0.66 ± 0.21 Gy, respectively. The difference between these 
two groups was statistically significant (p = 0.026). 
Regarding the type of pathology, absorbed dose to the 
blood was estimated 0.62 ± 0.20 and 0.66 ± 0.20 Gy, for 
patients with PTC and with FTC, respectively. The differ­
ence between these groups was not statistically significant 
(p = 0.951). 
Analysis of absorbed dose to the blood in patients 
with (0.62 ± 0.22 Gy) and without (0.63 ± 0.15 Gy) residual 
thyroid tissue after thyroidectomy revealed no difference 
between these two groups (p = 0.115). 
Also, the median absorbed dose to the blood in patients 
with lymph node metastases was estimated to be 0.67 ± 
0.23 and 0.58 ± 0.17 Gy without. Difference between these 
two groups was statistically significant (p = 0.036). 
The median absorbed dose to the blood for patients 
with regional metastases was 0.64 ± 0.18 and 0.61 ± 
0.22 Gy with out. The observed difference was not signif­
icant (p = 0.586). 
Finally, the absorbed dose to the blood in patients with 
distant metastases was estimated at 0.72 ± 0.12 Gy and at 
0.62 ± 0.21 Gy without. Statistical analysis of data revealed 
no significant difference in absorbed dose to the blood be­
tween the two groups (p = 0.155). T
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DISCUSSION 
In recommended protocols for DTC therapy, radio-
iodine ablation has long been associated with a lower rate 
of recurrence and distant metastases, as well as a reduced 
risk of cancer mortality, than undergoing only surgery 
(DeGroot et al. 1990; Massin et al. 1984; Mazzaferri 1997; 
Schlumberger 1998; Simpson et al. 1988; Tsang et al. 1998). 
While some physicians favor low radioiodine levels 
approximating 1.11 GBq, others prefer higher amounts of 
up to 7.4 GBq (Beierwaltes 1987; Hay et al. 2002; Ramanna 
et al. 1985). Furthermore, because of some technical diffi­
culties, physicians in most centers often use a predeter­
mined and fixed radioiodine level from 1.11 to 7.4 GBq 
rather than techniques based on bio-kinetic properties of 
patients (Bal et al. 2004). 
The British Thyroid Association guidelines, specifi­
cally, recommend radioiodine ablation after a total thy­
roidectomy for DTC patients with tumors larger than 
1 cm. While there is no agreement on the standard amount 
of radioiodine, an ablation dose of 3.7 GBq is usual, even 
though some centers prefer ablation doses as low as 1.11 
GBq (Watkinson et al. 2004). 
The European consensus report on ablation recom­
mends activity of 3.7 GBq for those DTC patients with a 
high risk of recurrence, distant metastases, or incomplete 
tumor resection (Pacini et al. 2005). 
From a historical point of view, it has long been ac­
cepted that a single administration of a higher radioiodine 
level results in a more successful ablation. This was based 
on the hypothesis that the larger the amount of radioiodine, 
the more likely it is than lower levels to ablate remnants and 
destroy residual micro-metastases (Beierwaltes et al. 1984). 
AQ4 A study by Mazzaferri and Kloost o of 30‐y recurrence 
rates of DTC patients treated with radioiodine ablation after 
their thyroidectomies found no significant difference be­
tween low-dose (1 to 1.85 GBq) and high-dose (1.89 to 
7.4 GBq) groups (Mazzaferri 1997). 
One benefit of lower radioiodine dosage is smoother 
outpatient treatment, because it reduces the radiation ex­
posure to the patient’s environment and household mem­
bers. As well, lower dosage also lowers financial cost, 
lessens the amount of time a patient spends in isolation, 
shortens hospital stays, and lowers whole-body irradia­
tion (DeGroot et al. 1990; Grigsby et al. 2000). Further­
more, because the risk of a second primary malignancy 
is correlated with radioiodine ablation, a lower dose re­
duces this risk (Rubino et al. 2003). 
While this study kept the amount of administered 
radioiodine relatively low, the authors evaluated whether 
higher doses would necessarily increase the absorbed dose 
to the blood. This study revealed that absorbed dose to the 
blood of patients with DTC administrated with 5.55 GBq 
of radioiodine is significantly higher than that of patients 
administrated with 3.7 GBq of radioiodine. However, 
there is no significant difference in the absorbed dose to 
patients’ blood when treated with 7.4 GBq of radioiodine 
compared to 5.55 GBq. Given that the absorbed dose to 
the blood is a better predictor of ablation success than over­
all radioiodine administered (Verburg et al. 2011), these 
findings suggest that 5.55 GBq would be the most favor­
able dose compared to 3.7 GBq and 7.4 GBq of radioiodine 
in thyroid ablation. Dosage of 5.55 GBq is not only more 
advantageous therapeutically, but it also causes fewer thera­
peutic problems than a dose of 7.4 GBq. 
These findings contrast the results of Mazzaferri on 
1004 DTC patients undergoing radioiodine ablation of 
thyroid remnant. That study categorized patients into two 
groups: those treated with 1–1.85 GBq (mean 1.74 GBq) 
of radioiodine and those treated with 1.89–7.4 GBq (mean 
4.1 GBq). That study observed no significant difference 
in recurrence rates between the two groups of patients 
(Mazzaferri 1997). One possible reason for this is that 
the current study used different values of radioiodine ac­
tivity in the ablations. The Mazzaferri study patients were 
administered various amounts of radioiodine ranging from 
1 GBq to 7.4 GBq, which made it impossible to assess the 
effect of each dose on the ablation’s overall success. As 
well, because this analysis used only two dose groups of less 
than and greater than 1.85 GBq, the current study was more 
nuanced, dividing patients into three dose groups of 3.7, 
5.55, and 7.4 GBq. 
The authors observed that the absorbed dose to the 
blood in female patients is significantly higher than in 
male patients. As well, absorbed dose to the blood is signif­
icantly higher in patients with lymph node metastases than 
without. This study also indicates that there is no correlation 
between absorbed dose to the blood and whether a patient 
has PTC or FTC pathology or regional or distant metastases. 
One of the main problems in this study was related 
to measuring whole-body dosage using a Geiger Muller 
dosimeter in which the operator was exposed to radioiodine 
radiation. In most advanced nuclear medicine centers, do­
simeter systems are launched 2 m above the patient’s coa ch AQ5 
ch to record external whole-body radiation. 
This study suffered from a shortage of patients under­
going a 7.4 GBq radioiodine dosage and a small overall 
sample of participating patients compared to other studies. 
Therefore, further research requires a larger number of 
patients split into more categories of radioiodine dosages 
to find the optimum activity for the best therapeutic abla­
tion outcomes. 
CONCLUSION 
There is no further increase in the overall activity per 
volume of blood when radioiodine ablation dosages exceed 
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5.55 GBq. The literature on this issue remains scarce, and
 
further studies are needed to verify these preliminary results.
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